The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during amivantamab therapy.
Alexander I. Spira, MD, PhD
Advertisement
Articles by Alexander I. Spira, MD, PhD
Advertisement
Latest Updated Articles
COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus LazertinibPublished: July 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism
2
Rural-Urban Disparities in Colorectal Cancer Screening Persist
3
Insurance Coverage Improves for Same-Sex Couples, Yet Disparities Persist
4
Medicare Beneficiaries With Near Low Income Face Highest Health Care Affordability Challenges
5
